Michael DiFiore
Stock Analyst at Evercore ISI
(1.04)
# 3,705
Out of 4,468 analysts
9
Total ratings
66.7%
Success rate
-5.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael DiFiore
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintained: Buy | $392 → $649 | $528.10 | +22.89% | 2 | May 7, 2026 | |
| VTVT vTv Therapeutics | Initiated Coverage: Buy | $44 | $35.26 | +24.79% | 1 | Mar 12, 2026 | |
| ALT Altimmune | Initiated Coverage: Buy | $25 | $3.16 | +691.14% | 1 | Aug 22, 2025 | |
| SKYE Skye Bioscience | Initiated Coverage: Buy | $10 | $0.7005 | +1,327.55% | 1 | Aug 15, 2025 | |
| HALO Halozyme Therapeutics | Reiterated: Buy | $55 | $79.45 | n/a | 2 | May 15, 2025 | |
| ATRA Atara Biotherapeutics | Downgraded: Hold | n/a | $11.65 | n/a | 1 | Nov 9, 2023 | |
| CLYM Climb Bio | Initiated Coverage: Buy | n/a | $12.90 | n/a | 1 | Sep 8, 2021 |
Madrigal Pharmaceuticals
May 7, 2026
Maintained: Buy
Price Target: $392 → $649
Current: $528.10
Upside: +22.89%
vTv Therapeutics
Mar 12, 2026
Initiated Coverage: Buy
Price Target: $44
Current: $35.26
Upside: +24.79%
Altimmune
Aug 22, 2025
Initiated Coverage: Buy
Price Target: $25
Current: $3.16
Upside: +691.14%
Skye Bioscience
Aug 15, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $0.7005
Upside: +1,327.55%
Halozyme Therapeutics
May 15, 2025
Reiterated: Buy
Price Target: $55
Current: $79.45
Upside: n/a
Atara Biotherapeutics
Nov 9, 2023
Downgraded: Hold
Price Target: n/a
Current: $11.65
Upside: n/a
Climb Bio
Sep 8, 2021
Initiated Coverage: Buy
Price Target: n/a
Current: $12.90
Upside: n/a